Fluorine in medicinal chemistry

Progress in Medicinal Chemistry

Volumn 54, Issue , 2015, Pages 65-133

  Swallow, Steven ^a  

^a ASTRAZENECA   (United Kingdom)

Author keywords

Conformational influences of fluorine; Fluorinated pharmaceuticals; Fluorine; Fluorine in medicinal chemistry; Impact of fluorine on lipophilicity; Impact of fluorine on physical properties; Impact of fluorine on pKa; Molecular interactions of fluorine with proteins; Toxic metabolites containing fluorine

Indexed keywords

APREPITANT; AROMATIC COMPOUND; CELECOXIB; EZETIMIBE; FLUCONAZOLE; FLUORINE; FLUTICASONE PROPIONATE; POTASSIUM CHANNEL HERG; QUINOLONE DERIVATIVE; SITAGLIPTIN; VORICONAZOLE;

ARTICLE; CONFORMATION; CONJUGATION; DIPOLE; LIPOPHILICITY; METABOLISM; METABOLITE; MOLECULAR INTERACTION; NONHUMAN; OXIDATION; PKA; PRIORITY JOURNAL; PROTEIN INTERACTION; ANIMAL; CHEMISTRY; HUMAN; MEDICINAL CHEMISTRY; SOLUBILITY;

ANIMALS; CHEMISTRY, PHARMACEUTICAL; FLUORINE; HUMANS; MOLECULAR CONFORMATION; SOLUBILITY;

EID: 84923106718     PISSN: 00796468     EISSN: 18757863     Source Type: Book Series    
DOI: 10.1016/bs.pmch.2014.11.001     Document Type: Chapter

References (131)

1. H. Moissan Action d'un courant électrique sur l'acide fluorhydrique anhydre C R Hebd Seances Acad Sci 102 1886 1543
2. H. Moissan Sur la décomposition de l'acide fluorhydrique par un courant électrique C R Hebd Seances Acad Sci 103 1886 202
3. R.H. Langley, and L. Welch Fluorine J Chem Educ 60 9 1983 759
4. D.L. Ostercamp, and R. Brunsvold Chemical aspects of general anesthesia: part I. From ether to halothane J Chem Educ 83 12 2006 1821
5. D.E. Halpern Fluorinated inhalation anesthetics R.E. Banks, B.E. Smart, J.C. Tatlow, Organofluorine chemistry 1994 Springer Science & Business Media New York 543
6. J. Fried, and E.F. Sabo 9α-Fluoro derivatives of cortisone and hydrocortisone J Am Chem Soc 76 5 1954 1455 1456
7. W.K. Hagmann The many roles for fluorine in medicinal chemistry J Med Chem 51 15 2008 4359 4369
8. C. Dalvit, C. Invernizzi, and A. Vulpetti Fluorine as a hydrogen-bond acceptor: experimental evidence and computational calculations Chem Eur J 20 35 2014 11058 11068
9. P.J. Hajduk, and D.R. Sauer Statistical analysis of the effects of common chemical substituents on ligand potency J Med Chem 51 3 2008 553 564
10. K. Müller, C. Faeh, and F. Diederich Fluorine in pharmaceuticals: looking beyond intuition Science 317 5846 2007 1881 1886
11. A.G. Dossetter, A. Douglas, and C. O'Donnell A matched molecular pair analysis of in vitro human microsomal metabolic stability measurements for heterocyclic replacements of di-substituted benzene containing compounds - identification of those isosteres more likely to have beneficial effects MedChemComm 3 9 2012 1164 1169
12. P.D. Leeson, and B. Springthorpe The influence of drug-like concepts on decision-making in medicinal chemistry Nat Rev Drug Discov 6 11 2007 881 890
13. T. Luker, L. Alcaraz, K.K. Chohan, N. Blomberg, D.S. Brown, and R.J. Butlin Strategies to improve in vivo toxicology outcomes for basic candidate drug molecules Bioorg Med Chem Lett 21 19 2011 5673 5679
14. M.P. Edwards, and D.A. Price Role of physicochemical properties and ligand lipophilicity efficiency in addressing drug safety risks J.E. Macor, Annual reports in medicinal chemistry 2010 Academic Press 380 391
15. P.W. Kenny Prediction of hydrogen bond basicity from computed molecular electrostatic properties: implications for comparative molecular field analysis J Chem Soc, Perkin Trans 2 2 1994 199 202
16. B.E. Smart Fluorine substituent effects (on bioactivity) J Fluor Chem 109 1 2001 3 11
17. H. Böhm, D. Banner, S. Bendels, M. Kansy, B. Kuhn, and K. Müller Fluorine in medicinal chemistry ChemBioChem 5 5 2004 637 643
18. Q.A. Huchet, B. Kuhn, B. Wagner, H. Fischer, M. Kansy, and D. Zimmerli On the polarity of partially fluorinated methyl groups J Fluor Chem 152 2013 119 128
19. D. Oehlrich, H. Prokopcova, and H.J.M. Gijsen The evolution of amidine-based brain penetrant BACE1 inhibitors Bioorg Med Chem Lett 24 9 2014 2033 2045
20. H. Shimizu, T. Yamasaki, Y. Yoneda, F. Muro, T. Hamada, and T. Yasukochi Discovery of imidazo[1,2-b]pyridazines as IKKβ inhibitors. Part 3: exploration of effective compounds in arthritis models Bioorg Med Chem Lett 21 15 2011 4550 4555
21. J. Winum, A. Scozzafava, J. Montero, and C.T. Supuran New zinc binding motifs in the design of selective carbonic anhydrase inhibitors Mini-Rev Med Chem 6 8 2006 921 936
22. T. Loftsson, P. Jansook, and E. Stefansson Topical drug delivery to the eye: dorzolamide Acta Ophthalmol 90 7 2012 603 608
23. M.A. Pinard, C.D. Boone, B.D. Rife, C.T. Supuran, and R. McKenna Structural study of interaction between brinzolamide and dorzolamide inhibition of human carbonic anhydrases Bioorg Med Chem 21 22 2013 7210 7215
24. T.H. Maren, and C.W. Conroy A new class of carbonic anhydrase inhibitor J Biol Chem 268 35 1993 26233 26239
25. K. Håkansson, and A. Liljas The structure of a complex between carbonic anhydrase II and a new inhibitor, trifluoromethane sulphonamide FEBS Lett 350 2-3 1994 319 322
26. M. Morgenthaler, E. Schweizer, A. Hoffmann-Roder, F. Benini, R.E. Martin, and G. Jaeschke Predicting and tuning physicochemical properties in lead optimization: Amine Basicities ChemMedChem 2 8 2007 1100
27. W.C. Black, C.I. Bayly, D.E. Davis, S. Desmarais, J. Falgueyret, and S. Léger Trifluoroethylamines as amide isosteres in inhibitors of cathepsin K Bioorg Med Chem Lett 15 21 2005 4741 4744
28. A. Volonterio, S. Bellosta, F. Bravin, M.C. Bellucci, L. Bruché, and G. Colombo Synthesis, structure and conformation of partially-modified retro- and retro-inverso ψ[NHCH(CF3)]gly peptides Chemistry 9 18 2003 4510 4522
29. M. Rowley, D.J. Hallett, S. Goodacre, C. Moyes, J. Crawforth, and T.J. Sparey 3-(4-Fluoropiperidin-3-yl)-2-phenylindoles as high affinity, selective, and orally bioavailable h5-HT2A receptor antagonists J Med Chem 44 10 2001 1603 1614
30. H. Hilpert, W. Guba, T.J. Woltering, W. Wostl, E. Pinard, and H. Mauser β-Secretase (BACE1) inhibitors with high in vivo efficacy suitable for clinical evaluation in Alzheimer's disease J Med Chem 56 10 2013 3980 3995
31. C.D. Cox, M.J. Breslin, D.B. Whitman, P.J. Coleman, R.M. Garbaccio, and M.E. Fraley Kinesin spindle protein (KSP) inhibitors. Part V: discovery of 2-propylamino-2,4-diaryl-2,5-dihydropyrroles as potent, water-soluble KSP inhibitors, and modulation of their basicity by β-fluorination to overcome cellular efflux by P-glycoprotein Bioorg Med Chem Lett 17 10 2007 2697 2702
32. C.D. Cox, P.J. Coleman, M.J. Breslin, D.B. Whitman, R.M. Garbaccio, and M.E. Fraley Kinesin spindle protein (KSP) inhibitors. 9. Discovery of (2S)-4-(2,5-difluorophenyl)-N-(3R,4S)-3-fluoro-1-methylpiperidin-4-yl]-2-(hydroxymethyl)-N-methyl-2-phenyl-2,5-dihydro-1H-pyrrole-1-carboxamide (MK-0731) for the treatment of taxane-refractory cancer J Med Chem 51 14 2008 4239 4252
33. K. Finlayson, H.J. Witchel, J. McCulloch, and J. Sharkey Acquired QT interval prolongation and HERG: implications for drug discovery and development Eur J Pharmacol 500 1-3 Spec. Iss 2004 129 142
34. A.M. Aronov Ligand structural aspects of hERG channel blockade Curr Top Med Chem (Sharjah, United Arab Emirates) 8 13 2008 1113 1127
35. F. Reck, R.A. Alm, P. Brassil, J.V. Newman, P. Ciaccio, and J. McNulty Novel N-linked aminopiperidine inhibitors of bacterial topoisomerase type II with reduced pKa: antibacterial agents with an improved safety profile J Med Chem 55 15 2012 6916 6933
36. T.S. Reger, Z. Yang, K.S. Schlegel, Y. Shu, C. Mattern, and R. Cube Pyridyl amides as potent inhibitors of T-type calcium channels Bioorg Med Chem Lett 21 6 2011 1692 1696
37. L.R. Fish, M.T. Gilligan, A.C. Humphries, M. Ivarsson, T. Ladduwahetty, and K.J. Merchant 4-Fluorosulfonylpiperidines: selective 5-HT2A ligands for the treatment of insomnia Bioorg Med Chem Lett 15 16 2005 3665 3669
38. I.T. Huscroft, E.J. Carlson, G.G. Chicchi, M.M. Kurtz, C. London, and P. Raubo 1-Phenyl-8-azabicyclo[3.2.1]octane ethers: a novel series of neurokinin (NK1) antagonists Bioorg Med Chem Lett 16 7 2006 2008 2012
39. A.G. Dossetter A statistical analysis of in vitro human microsomal metabolic stability of small phenyl group substituents, leading to improved design sets for parallel SAR exploration of a chemical series Bioorg Med Chem 18 12 2010 4405 4414
40. A.J. Barker, K.H. Gibson, W. Grundy, A.A. Godfrey, J.J. Barlow, and M.P. Healy Studies leading to the identification of ZD1839 (iressa™): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer Bioorg Med Chem Lett 11 14 2001 1911 1914
41. A.S. Kalgutkar, I. Gardner, R.S. Obach, C.L. Shaffer, E. Callegari, and K.R. Henne A comprehensive listing of bioactivation pathways of organic functional groups Curr Drug Metab 6 2005 161 225
42. Y. Wu, C.D. Davis, S. Dworetzky, W.C. Fitzpatrick, D. Harden, and H. He Fluorine substitution can block CYP3A4 metabolism-dependent inhibition: identification of (S)-N-1-(4-fluoro-3-morpholin-4-ylphenyl)ethyl]-3-(4-fluorophenyl)acrylamide as an orally bioavailable KCNQ2 opener devoid of CYP3A4 metabolism-dependent inhibition J Med Chem 46 18 2003 3778 3781
43. M.F. Brown, M. Avery, W.H. Brissette, J.H. Chang, K. Colizza, and M. Conklyn Novel CCR1 antagonists with improved metabolic stability Bioorg Med Chem Lett 14 9 2004 2175 2179
44. J.C. Kath, A.P. DiRico, R.P. Gladue, W.H. Martin, E.B. McElroy, and I.A. Stock The discovery of structurally novel CCR1 antagonists derived from a hydroxyethylene peptide isostere template Bioorg Med Chem Lett 14 9 2004 2163 2167
45. Z. Huang, Y. Ducharme, D. Macdonald, and A. Robichaud The next generation of PDE4 inhibitors Curr Opin Chem Biol 5 4 2001 432 438
46. N. Chauret, D. Guay, C. Li, S. Day, J. Silva, and M. Blouin Improving metabolic stability of phosphodiesterase-4 inhibitors containing a substituted catechol: prevention of reactive intermediate formation and covalent binding Bioorg Med Chem Lett 12 16 2002 2149 2152
47. D. Guay, P. Hamel, M. Blouin, C. Brideau, C.C. Chan, and N. Chauret Discovery of L-791,943: a potent, selective, nonemetic and orally active phosphodiesterase-4 inhibitor Bioorg Med Chem Lett 12 11 2002 1457 1461
48. D.P. Tashkin Roflumilast: the new orally active, selective phophodiesterase-4 inhibitor, for the treatment of COPD Expert Opin Pharmacother 15 1 2014 85 96
49. C.T. Eason, and P. Turck A 90-day toxicological evaluation of compound 1080 (sodium monofluoroacetate) in Sprague-Dawley rats Toxicol Sci 69 2 2002 439 447
50. D.R. Hodgson, S.M. Fearnside, J. Heller, and N. Malikides Sodium monofluoroacetate (Compound 1080) poisoning in dogs Aust Vet J 83 8 2005 474 479
51. H. Lauble, M. Kennedy, M. Emptage, H. Beinert, and C. Stout The reaction of fluorocitrate with aconitase and the crystal structure of the enzyme-inhibitor complex Proc Natl Acad Sci USA 93 24 1996 13699 13703
52. F.R. Johannsen, and C.O. Knowles Toxicity and action of fluenethyl acaricide and related compounds in the mouse, housefly and twospotted spider mite Comp Gen Pharmacol 5 1 1974 101 110
53. B.A. Saxty, R. Novelli, R.E. Dolle, L.I. Kruse, D.G. Reid, and P. Camilleri Synthesis and evaluation of (+) and (-)-2,2-difluorocitrate as inhibitors of rat-liver ATP-citrate lyase and porcine-heart aconitase Eur J Biochem 202 3 1991 889 896
54. N. Zhang, X. Zhang, J. Zhu, A. Turpoff, G. Chen, and C. Morrill Structure-activity relationship (SAR) optimization of 6-(indol-2-yl)pyridine-3-sulfonamides: identification of potent, selective, and orally bioavailable small molecules targeting hepatitis C (HCV) NS4B J Med Chem 57 2014 2121
55. K.I. Menon, M.G. Feldwick, P.S. Noakes, and R.J. Mead The mode of toxic action of the pesticide Gliftor: the metabolism of 1,3-difluoroacetone to (-)-erythro-fluorocitrate J Biochem Mol Toxicol 15 1 2001 47 54
56. S.C. Lloyd, D.M. Blackburn, and P.M.D. Foster Trifluoroethanol and its oxidative metabolites: comparison of in vivo and in vitro effects in the rat testis Food Chem Toxicol 24 6-7 1986 653 654
57. M.E. Dowty, G. Hu, F. Hua, F.B. Shilliday, and H.V. Dowty Drug design structural alert: formation of trifluoroacetaldehyde through N-dealkylation is linked to testicular lesions in rat Int J Toxicol 30 5 2011 546 550
58. R. Paulini, K. Müller, and F. Diederich Orthogonal multipolar interactions in structural chemistry and biology Angew Chem Int Ed Engl 44 12 2005 1788 1805
59. D.M. Goldstein, M. Soth, T. Gabriel, N. Dewdney, A. Kuglstatter, and H. Arzeno Discovery of 6-(2,4-difluorophenoxy)-2-3-hydroxy-1-(2-hydroxyethyl)propylamino]-8-methyl-8H-pyrido2,3-d]pyrimidin-7-one (pamapimod) and 6-(2,4-difluorophenoxy)-8-methyl-2-(tetrahydro-2H-pyran-4-ylamino)pyrido2,3-d]pyrimidin-7(8H)-one (R1487) as orally bioavailable and highly selective inhibitors of p38α mitogen-activated protein kinase J Med Chem 54 7 2011 2255 2265
60. A. Vulpetti, U. Hommel, G. Landrum, R. Lewis, and C. Dalvit Design and NMR-based screening of LEF, a library of chemical fragments with different local environment of fluorine J Am Chem Soc 131 36 2009 12949 12959
61. A. Vulpetti, and C. Dalvit Fluorine local environment: from screening to drug design Drug Discov Today 17 15-16 2012 890 897
62. X. Deng, S. Kokkonda, F. El Mazouni, J. White, J.N. Burrows, and W. Kaminsky Fluorine modulates species selectivity in the triazolopyrimidine class of plasmodium falciparum dihydroorotate dehydrogenase inhibitors J Med Chem 57 12 2014 5381 5394
63. D. O'Hagan Understanding organofluorine chemistry. An introduction to the C-F bond Chem Soc Rev 37 2 2008 308 319
64. L. Hunter The C-F bond as a conformational tool in organic and biological chemistry Beilstein J Org Chem 6 2010 38
65. J. Nieschalk, A.S. Batsanov, D. O'Hagan, and J. Howard Synthesis of monofluoro- and difluoro-methylenephosphonate analogues of sn-glycerol-3-phosphate as substrates for glycerol-3-phosphate dehydrogenase and the X-ray structure of the fluoromethylenephosphonate moiety Tetrahedron 52 1 1996 165 176
66. P.W. Chia, M.R. Livesey, A.M.Z. Slawin, T. van-Mourik, D.J.A. Wyllie, and D. O'Hagan 3-Fluoro-N-methyl-d-aspartic acid (3F-NMDA) stereoisomers as conformational probes for exploring agonist binding at NMDA receptors Chem Eur J 18 28 2012 8813 8819
67. A.G. Myers, J.K. Barbay, and B. Zhong Asymmetric synthesis of chiral organofluorine compounds: use of nonracemic fluoroiodoacetic acid as a practical electrophile and its application to the synthesis of monofluoro hydroxyethylene dipeptide isosteres within a novel series of HIV protease inhibitors J Am Chem Soc 123 30 2001 7207 7219
68. W. Meng, and F. Qing Fluorinated nucleosides as antiviral and antitumor agents Curr Top Med Chem (Sharjah, United Arab Emirates) 6 14 2006 1499 1528
69. P. Liu, A. Sharon, and C.K. Chu Fluorinated nucleosides: synthesis and biological implication J Fluor Chem 129 9 2008 743 766
70. F. Zheng, X. Qiu, and F. Qing Synthesis and antiviral, antitumour activities of fluorinated sugar nucleosides Mol Med Med Chem 6 2012 241 297
71. H. Wojtowicz-Rajchel Synthesis and applications of fluorinated nucleoside analogues J Fluor Chem 143 2012 11 48
72. V.E. Marquez, A. Ezzitouni, P. Russ, M.A. Siddiqui, H. Ford, and R.J. Feldman HIV-1 reverse transcriptase can discriminate between two conformationally locked carbocyclic AZT triphosphate analogues J Am Chem Soc 120 12 1998 2780 2789
73. V.E. Marquez, T. Ben-Kasus, J.J. Barchi, K.M. Green, M.C. Nicklaus, and R. Agbaria Experimental and structural evidence that herpes 1 kinase and cellular DNA polymerase(s) discriminate on the basis of sugar pucker J Am Chem Soc 126 2 2004 543 549
74. J.J. Barchi Jr., R.G. Karki, M.C. Nicklaus, M.A. Siddiqui, C. George, and I.A. Mikhailopulo Comprehensive structural studies of 2',3'-difluorinated nucleosides: comparison of theory, solution, and solid state J Am Chem Soc 130 28 2008 9048 9057
75. S. Martinez-Montero, G.F. Deleavey, A. Kulkarni, N. Martin-Pintado, P. Lindovska, and M. Thomson Rigid 2',4'-difluororibonucleosides: synthesis, conformational analysis, and incorporation into nascent RNA by HCV polymerase J Org Chem 79 12 2014 5627 5635
76. M.J. Sofia, D. Bao, W. Chang, J. Du, D. Nagarathnam, and S. Rachakonda Discovery of a β-d-2′-deoxy-2′-α-fluoro-2′-β-C-methyluridine nucleotide prodrug (PSI-7977) for the treatment of hepatitis C virus J Med Chem 53 19 2010 7202 7218
77. C.R.S. Briggs, D. O'Hagan, J.A.K. Howard, and D.S. Yufit The C-F bond as a tool in the conformational control of amides J Fluor Chem 119 1 2003 9 13
78. J.W. Banks, A.S. Batsanov, J.A.K. Howard, D. O'Hagan, H.S. Rzepa, and S. Martin-Santamaria The preferred conformation of small alpha-fluoroamides J Chem Soc, Perkin Trans 2 11 1999 2409 2411
79. M. Winkler, T. Moraux, H.A. Khairy, R.H. Scott, A.M.Z. Slawin, and D. O'Hagan Synthesis and vanilloid receptor (TRPV1) activity of the enantiomers of α-fluorinated capsaicin ChemBioChem 10 5 2009 823 828
80. J. Earl, and P. Kirkpatrick Ezetimibe Nat Rev Drug Discov 2 2 2003 97 98
81. S.B. Rosenblum, T. Huynh, A. Afonso, H.R. Davis, N. Yumibe, and J.W. Clader Discovery of 1-(4-fluorophenyl)-(3R)-3-(4-fluorophenyl)-(3S)-hydroxypropyl]-(4S)-(4-hydroxyphenyl)-2-azetidinone (SCH 58235): a designed, potent, orally active inhibitor of cholesterol absorption J Med Chem 41 6 1998 973 980
82. M. Van Heek, C.F. France, D.S. Compton, R.L. McLeod, N.P. Yumibe, and K.B. Alton In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461 J Pharmacol Exp Ther 283 1 1997 157 163
83. M.E. Sweeney, and R.R. Johnson Ezetimibe: an update on the mechanism of action, pharmacokinetics and recent clinical trials Expert Opin Drug Metab Toxicol 3 3 2007 441 450
84. P. McCormack Celecoxib Drugs 71 18 2011 2457 2489
85. T.D. Penning, J.J. Talley, S.R. Bertenshaw, J.S. Carter, P.W. Collins, and S. Docter Synthesis and biological evaluation of the 1,5-diarylpyrazole class of cyclooxygenase-2 inhibitors: identification of 4-[5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl]benze nesulfonamide (SC-58635, celecoxib) J Med Chem 40 9 1997 1347
86. D.J. Drucker, and M.A. Nauck The incretin system: glucagon-like peptide-1 receptor agonists and dipeptidyl peptidase-4 inhibitors in type 2 diabetes Lancet 368 9548 2006 1696 1705
87. A.E. Weber, and N. Thornberry Case history: JANUVIA (sitagliptin), a selective dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes Annu Rep Med Chem 42 2007 95 109
88. J. Xu, H.O. Ok, E.J. Gonzalez, L.F. Colwell, B. Habulihaz, and H. He Discovery of potent and selective β-homophenylalanine based dipeptidyl peptidase IV inhibitors Bioorg Med Chem Lett 14 18 2004 4759 4762
89. L.L. Brockunier, J. He, L.F. Colwell, B. Habulihaz, H. He, and B. Leiting Substituted piperazines as novel dipeptidyl peptidase IV inhibitors Bioorg Med Chem Lett 14 18 2004 4763 4766
90. D. Kim, L. Wang, M. Beconi, G.J. Eiermann, M.H. Fisher, and H. He (2R)-4-Oxo-4-3-(Trifluoromethyl)-5,6-dihydro1,2,4]triazolo4,3-A]pyrazin-7(8H)-yl]-1-(2,4,5-trifluorophenyl)butan-2-amine: a potent, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes J Med Chem 48 1 2005 141 151
91. A. Bergman, D. Ebel, F. Liu, J. Stone, A. Wang, and W. Zeng Absolute bioavailability of sitagliptin, an oral dipeptidyl peptidase-4 inhibitor, in healthy volunteers Biopharm Drug Dispos 28 6 2007 315 322
92. D. Kim, J.E. Kowalchick, S.D. Edmondson, A. Mastracchio, J. Xu, and G.J. Eiermann Triazolopiperazine-amides as dipeptidyl peptidase IV inhibitors: close analogs of JANUVIA (sitagliptin phosphate) Bioorg Med Chem Lett 17 12 2007 3373 3377
93. B. Kuhn, M. Hennig, and P. Mattei Molecular recognition of ligands in dipeptidyl peptidase IV Curr Top Med Chem 7 6 2007 609 620
94. E.S. Istvan, and J. Deisenhofer Structural mechanism for statin inhibition of HMG-CoA reductase Science 292 5519 2001 1160
95. B.D. Roth, D.F. Ortwine, M.L. Hoefle, C.D. Stratton, D.R. Sliskovic, and M.W. Wilson Inhibitors of cholesterol biosynthesis. 1. trans-6-(2-Pyrrol-1-ylethyl)-4-hydroxypyran-2-ones, a novel series of HMG-CoA reductase inhibitors. 1. Effects of structural modifications at the 2- and 5-positions of the pyrrole nucleus J Med Chem 33 1 1990 21 31
96. K. Richardson The discovery of fluconazole Contemp Org Synth 3 2 1996 125 132
97. R.P. Dickinson, A.S. Bell, C.A. Hitchcock, S. Narayanaswami, S.J. Ray, and K. Richardson Novel antifungal 2-aryl-1-(1H-1,2,4-triazol-1-yl)butan-2-ol derivatives with high activity against Aspergillus fumigatus Bioorg Med Chem Lett 6 16 1996 2031 2036
98. S.J. Roffey, S. Cole, P. Comby, D. Gibson, S.G. Jezequel, and A.N.R. Nedderman The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human Drug Metab Dispos 31 6 2003 731 741
99. A.L. Barry, and S.D. Brown In vitro studies of two triazole antifungal agents (voriconazole UK-109,496] and fluconazole) against Candida species Antimicrob Agents Chemother 40 8 1996 1948 1949
100. M.I. Andersson, and A.P. MacGowan Development of the quinolones J Antimicrob Chemother 51 2003 1 11
101. J.M. Domagala, L.D. Hanna, C.L. Heifetz, M.P. Hutt, T.F. Mich, and J.P. Sanchez New structure-activity relationships of the quinolone antibacterials using the target enzyme. The development and application of a DNA gyrase assay J Med Chem 29 3 1986 394 404
102. Y. Kimura, S. Atarashi, K. Kawakami, K. Sato, and I. Hayakawa (Fluorocyclopropyl)quinolones. 2. Synthesis and stereochemical structure-activity relationships of chiral 7-(7-amino-5-azaspiro[2.4]heptan-5-yl)-1-(2-fluorocyclopropyl)quinolone antibacterial agents J Med Chem 37 20 1994 3344 3352
103. G.H. Phillipps Locally active corticosteroids: structure activity relationships L. Wilson, R. Markes, Mechanisms of topical corticosteroid activity 2009 Churchill Livingstone London 1
104. B.M. Bain, P.J. May, G.H. Phillipps, and E.A. Woollett Anti-inflammatory esters of steroidal carboxylic acids J Steroid Biochem 5 1974 299
105. G.H. Phillipps Structure-activity relationships of topically active steroids: the selection of fluticasone propionate Respir Med 84 Suppl. A 1990 19 23
106. G.H. Phillipps, E.J. Bailey, B.M. Bain, R.A. Borella, J.B. Buckton, and J.C. Clark Synthesis and structure-activity relationships in a series of antiinflammatory corticosteroid analogs, halomethyl androstane-17beta-carbothioates and -17beta.carboselenoates J Med Chem 37 22 1994 3717 3729
107. S.M. Harding The human pharmacology of fluticasone propionate Respir Med 84 Suppl. A 1990 25 29
108. T.S. Berger, Z. Parandoosh, B.W. Perry, and R.B. Stein Interaction of glucocorticoid analogues with the human glucocorticoid receptor J Steroid Biochem Mol Biol 41 3-8 1992 733 738
109. P. Genard, and M. Palem-Vliers Role of hydrophobic effects and polar groups in steroid-mineralocorticoid receptor interactions J Steroid Biochem 19 5 1983 1639 1645
110. K. Biggadike, R.K. Bledsoe, A.M. Hassell, B.E. Kirk, I.M. McLay, and L.M. Shewchuk X-ray crystal structure of the novel enhanced-affinity glucocorticoid agonist fluticasone furoate in the glucocorticoid receptor-ligand binding domain J Med Chem 51 12 2008 3349 3352
111. R.K. Bledsoe, V.G. Montana, T.B. Stanley, C.J. Delves, C.J. Apolito, and D.D. McKee Crystal structure of the glucocorticoid receptor ligand binding domain reveals a novel mode of receptor dimerization and coactivator recognition Cell 110 1 2002 93 105
112. B. Kauppi, C. Jakob, M. Faernegardh, J. Yang, H. Ahola, and M. Alarcon The three-dimensional structures of antagonistic and agonistic forms of the glucocorticoid receptor ligand-binding domain: RU-486 induces a transconformation that leads to active antagonism J Biol Chem 278 25 2003 22748 22754
113. W.L. Mock, and J.Z. Zhang Concerning the relative acidities of simple alcohols Tetrahedron Lett 31 40 1990 5687 5688
114. J.M. Humphrey Medicinal chemistry of selective neurokinin-1 antagonists Curr Top Med Chem (Sharjah, United Arab Emirates) 3 12 2003 1423 1435
115. B.J. Williams, M.A. Teall, J. Kenna, T. Harrison, C.J. Swain, and M.A. Cascieri Acyclic NK-1 antagonists: 2-benzhydryl-2-aminoethyl ethers Bioorg Med Chem Lett 16 4 1994 1903 1908
116. A.P. Owens, B.J. Williams, T. Harrison, C.J. Swain, R. Baker, and S. Sadowski Phenylglycinol-based NK1 receptor antagonists - towards the minimum pharmacophore Bioorg Med Chem Lett 5 22 1995 2761 2766
117. T. Harrison, B.J. Williams, C.J. Swain, and R.G. Ball Piperidine-ether based hNK1 antagonists. 1: determination of the relative and absolute stereochemical requirements Bioorg Med Chem Lett 4 21 1994 2545 2550
118. J.J. Hale, S.G. Mills, M. MacCoss, S.K. Shah, H. Qi, and D.J. Mathre 2(S)-((3,5-Bis(trifluoromethyl)benzyl)oxy)-3(S)-phenyl-4-((3-oxo-1,2,4-triazol-5-yl)methyl)morpholine (1): a potent, orally active, morpholine-based human neurokinin-1 receptor antagonist J Med Chem 39 9 1996 1760 1762
119. T. Harrison, A.P. Owens, B.J. Williams, C.J. Swain, R. Baker, and P.H. Hutson Piperidine-ether based hNK1 antagonists. 2. Investigation of the effect of N-substitution Bioorg Med Chem Lett 5 3 1995 209 212
120. J.J. Hale, S.G. Mills, M. MacCoss, P.E. Finke, M.A. Cascieri, and S. Sadowski Structural optimization affording 2-(R)-(1-(R)-3,5-bis(trifluoromethyl)phenylethoxy)-3-(S)-(4-fluoro)phenyl-4-(3-oxo-1,2,4-triazol-5-yl)methylmorpholine, a potent, orally active, long-acting morpholine acetal human NK-1 receptor antagonist J Med Chem 41 23 1998 4607 4614
121. S.W. Huskey, B.J. Dean, G.A. Doss, Z. Wang, C.E.C.A. Hop, and R. Anari The metabolic disposition of aprepitant, a substance P receptor antagonist, in rats and dogs Drug Metab Dispos 32 2 2004 246 258
122. C. Chavez-Eng, M.L. Constanzer, and B.K. Matuszewski Simultaneous determination of Aprepitant and two metabolites in human plasma by high-performance liquid chromatography with tandem mass spectrometric detection J Pharm Biomed Anal 35 5 2004 1213 1229
123. K. Muller, and H. Bohm Facilitating the design of fluorinated drugs Chem Biol (Cambridge, MA) 16 11 2009 1130 1131
124. C.W. Kee, K.F. Chin, M.W. Wong, and C. Tan Selective fluorination of alkyl C-H bonds via photocatalysis Chem Commun 50 60 2014 8211 8214
125. J. Xia, Y. Ma, and C. Chen Vanadium-catalyzed C(sp3)-H fluorination reactions Org Chem Front 1 5 2014 468 472
126. G.K.S. Prakash, F. Wang, D. O'Hagan, J. Hu, K. Ding, and L.-X. Dai Flourishing frontiers in organofluorine chemistry K. Ding, L-X. Dai, Organic Chemistry - Breakthroughs and Perspectives. Germany: Wiley-VCH Verlag GmbH & Co. KGaA 2012 413 476
127. K.B. McMurtrey, and M.S. Sanford C-F bond forming reactions G.A. Molander, J.P. Wolfe, M. Larhed, Science of Synthesis. Cross coupling and Heck reactions 2 2013 Georg Thieme Verlag Stuttgart 551 564
128. Y. Li, Y. Wu, G. Li, and X. Wang Palladium-catalyzed C-F bond formation via directed C-H activation Adv Synth Catal 356 7 2014 1412 1418
129. H.M. Hugel, and N. Jackson Special feature organo-fluorine chemical science Appl Sci 2 2 2012 558 565
130. N. Al-Maharik, and D. O'Hagan Organofluorine chemistry. Deoxyfluorination reagents for C-F bond synthesis Aldrichim Acta 44 3 2011 65 75
131. J. Wu Review of recent advances in nucleophilic C-F bond-forming reactions at sp3 centers Tetrahedron Lett 55 31 2014 4289 4294